Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3760/cma.j.issn.1001-0939.2020.0002 http://scihub22266oqcxt.onion/10.3760/cma.j.issn.1001-0939.2020.0002 32023685!ä!32023685 Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538 Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538       Zhonghua+Jie+He+He+Hu+Xi+Za+Zhi 2020 ; 43 (ä): E002 Nephropedia Template TP {{tp|p=32023685|t=2020. Potential antiviral therapeutics for 2019 Novel Coronavirus |pdf=|usr=}}{{32023685}} gab.com Text Potential antiviral therapeutics for 2019 Novel Coronavirus JO: Zhonghua Jie He He Hu Xi Za Zhi http://www.kidney.de/pget.php?&tw=1&pmid=32023685 #FOAvip The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-beta, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials. Twit Text FOAVip Potential antiviral therapeutics for 2019 Novel Coronavirus ????Zhonghua Jie He He Hu Xi Za Zhi http://www.kidney.de/pget.php?&tw=1&pmid=32023685 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32023685 #FOAvip English Wikipedia <ref>{{Cite pmid|32023685}}</ref> Potential antiviral therapeutics for 2019 Novel Coronavirus #MMPMID32023685 Li H; Wang YM; Xu JY; Cao B Zhonghua Jie He He Hu Xi Za Zhi 2020[Feb]; 43 (ä): E002 PMID32023685show ga The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-beta, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials. ä Potential antiviral therapeutics for 2019 Novel Coronavirus (epmc).pdf DeepDyve Pubget Overpricing